Peptidyl-prolyl cis-trans isomerase FKBP1A–Protein phosphatase 3 catalytic subunit alpha complex (FKBP12–PPP3CA complex)

The FKBP12–PPP3CA complex is a ternary molecular assembly formed when the immunophilin FKBP12 (Peptidyl-prolyl cis-trans isomerase FKBP1A) binds to immunosuppressive drugs like Tacrolimus, subsequently associating with and inhibiting the phosphatase Calcineurin (PPP3CA) [1][2]. Calcineurin is a calcium-dependent serine/threonine protein phosphatase that plays a pivotal role in T-cell activation by dephosphorylating the Nuclear Factor of Activated T-cells (NFAT) [3]. Once dephosphorylated, NFAT translocates to the nucleus to induce the expression of interleukin-2 (IL-2) and other cytokines essential for the immune response [4]. By inhibiting this complex, drugs like Tacrolimus effectively suppress T-cell mediated immunity, making this target vital for preventing organ transplant rejection and managing autoimmune disorders [5]. However, the ubiquitous expression of calcineurin leads to significant off-target effects in the kidneys and nervous system, necessitating careful therapeutic drug monitoring [6]. This complex represents a classic example of a 'gain-of-function' drug mechanism where a small molecule mediates a protein-protein interaction to inhibit an enzyme [7]. Beyond systemic transplantation use, this pathway is also targeted topically for dermatological conditions like atopic dermatitis using pimecrolimus [8].

Other names

FKBP12-Calcineurin complexFK506-FKBP12-Calcineurin complexFKBP1A-PPP3CA complexTacrolimus-FKBP12-Calcineurin complexFKBP12-PPP3CA-PPP3R1 complex

Tacrolimus binds to the immunophilin FKBP12 to form a gain-of-function complex that physically blocks the active site of calcineurin (PPP3CA), inhibiting its phosphatase activity and preventing the dephosphorylation and nuclear translocation of NFAT.